
Jury Awards $90M Over Autoimmune Drug Licensing Dispute
A federal jury in San Francisco awarded Nektar Therapeutics $90 million against Eli Lilly and Company in a dispute over the autoimmune drug candidate rezpegaldesleukin (REZPEG). Nektar alleged that Lilly undermined REZPEG after acquiring a competing eczema drug, citing miscalculated trial data and a stalled Phase 2 program. The jury rejected Nektar’s breach of contract claim but found Lilly breached the implied covenant of good faith and fair dealing. Post-trial motions are pending.








